Abbvie Inc
NYSE:ABBV
Abbvie Inc
NYSE:ABBV
Price:
164.66 USD
0.25%
Market Closed
Updated:
Apr 19, 2024
Abbvie Inc
Cost of Revenue
Last
Value
3-Years CAGR
5-Years CAGR
|
Abbvie Inc
Cost of Revenue Peer Comparison
Comparables:
GILD
AMGN
VRTX
REGN
SGEN
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
$-18.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
$-6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
$-8.4B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
$-1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
$-1.8B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-28%
|
|
|
Seagen Inc
NASDAQ:SGEN
|
Cost of Revenue
$-566m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
-41%
|
See Also
What is Abbvie Inc's Cost of Revenue?
Cost of Revenue
-18.2B
USD
-18.2B
USD
Based on the financial report for Dec 31, 2023, Abbvie Inc's Cost of Revenue amounts to -18.2B USD.
What is Abbvie Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-15%
-15%
Over the last year, the Cost of Revenue growth was -10%. The average annual Cost of Revenue growth rates for Abbvie Inc have been -6% over the past three years , -19% over the past five years , and -15% over the past ten years .
You don't have any saved screeners yet
